TAMPA, Fla., Nov. 27, 2017 /PRNewswire/ — Teewinot Life Sciences Corporation (“Teewinot”), is an international cannabinoid biotechnology company focused on advanced pharmaceutical research and commercialization. Teewinot is a leader in the formulation, manufacturing, and delivery of pharmaceutical therapies containing cannabinoids, cannabinoid prodrugs, and cannabinoid analogs.Â Teewinot announced today it will be presenting at CBI’s Biopharma Forum on Cannabis-Based Therapies conference on Thursday, November 30th in Denver, CO.
Dr. Richard Peet, Teewinot’s Executive Vice President and Chief Intellectual Property Counsel, will present a lecture entitled “Mastering Clinical Trials for Emerging Cannabis Therapies.” Dr. Peet’s lecture will focus on Teewinot’s revolutionary and patent-protected processes for the manufacture of kilogram quantities of 18 naturally-occurring cannabinoids, in pharmaceutically pure form, by means of biocatalysis and synthetic biology. Dr. Peet’s lecture will also describe Teewinot’s preclinical studies in the area of inflammation.
Teewinot’s biosynthetic processes, referred
... read more at: http://markets.businessinsider.com/news/stocks/Teewinot-Life-Sciences-Corporation-a-Global-Leader-in-Pharmaceutical-Cannabinoid-Production-to-Present-at-CBI-s-Biopharma-Forum-on-Cannabis-Based-Therapies-1009675285